Yangyin Huowei mixture alleviates chronic atrophic gastritis by inhibiting the IL-10/JAK1/STAT3 pathway

doi:10.4240/wjgs.v16.i7.2296

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2023)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

1086

Figures (1-6)

268

Tables (1-4)

227

Sum=1624

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

287

Sum=336

Jul 27, 2024 (publication date) through Apr 6, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastrointest Surg. Jul 27, 2024; 16(7): 2296-2307
Published online Jul 27, 2024. doi: 10.4240/wjgs.v16.i7.2296

Table 1 Effects of Yangyin Huowei mixture on body mass, diet quantity, and fecal water content of rats (mean ± SD)

Group	Intervention time	n	Body mass (g)	Water intake (mL)	Food intake (g)	Fecal water content (g/%)
Blank control	Week 0	10	418.32 ± 22.36^b^,^c	47.38 ± 2.59^b	32.36 ± 2.96	72.23 ± 5.03^b
	Week 2	10	423.16 ± 20.88^b^,^c	47.55 ± 3.68^b	30.88 ± 1.79	70.75 ± 3.67^b
	Week 4	10	451.22 ± 21.84^b^,^c	46.69 ± 3.28^b	29.84 ± 2.55	69.71 ± 4.25^b
	Week 6	10	472.12 ± 22.36^b^,^c	53.72 ± 2.80^b	28.36 ± 2.51	68.23 ± 3.18^b
	Week 8	10	499.24 ± 22.75^b^,^c	54.07 ± 4.74^b	32.75 ± 2.79	72.62 ± 3.53^b
Model	Week 0	10	378.75 ± 18.78^a	62.47 ± 5.79^a	26.84 ± 1.94^a	66.71 ± 5.70^a
	Week 2	10	399.32 ± 18.68^a	60.92 ± 3.76^a^,^c	28.26 ± 2.37^a	58.13 ± 4.95^a^,^c
	Week 4	10	410.27 ± 18.35^a	63.50 ± 6.33^a^,^c	30.65 ± 2.35^a	60.52 ± 4.69^a^,^c
	Week 6	10	418.16 ± 20.07^a	56.47 ± 4.02^a^,^c	25.78 ± 2.01^a	61.65 ± 3.72^a^,^c
	Week 8	10	439.72 ± 17.20^a^,^c	65.90 ± 4.79^a^,^c	27.78 ± 2.08^a^,^c	57.65 ± 5.01^a^,^c
Low-dose YYHWM	Week 0	11	370.24 ± 17.58^a	60.58 ± 4.68^a	27.40 ± 1.44^a	65.27 ± 4.18^a
	Week 2	11	389.76 ± 16.91^a	53.04 ± 5.77^b	30.64 ± 3.26^a	70.51 ± 5.23^b
	Week 4	11	402.16 ± 19.02^a	52.69 ± 4.70^b	28.78 ± 2.27^a	68.65 ± 5.09^b
	Week 6	11	424.92 ± 15.33^a	40.69 ± 4.13^b	26.68 ± 2.61^a	66.55 ± 4.93^b
	Week 8	11	448.38 ± 16.91^a	52.01 ± 4.09^b	26.35 ± 3.38^a^,^c	66.22 ± 3.52^b^,^c
Medium-dose YYHWM	Week 0	11	368.71 ± 16.86^a	61.83 ± 3.49^a	27.07 ± 2.19^a	66.94 ± 2.75^a
	Week 2	11	379.73 ± 16.58^a	52.69 ± 3.82^b	31.72 ± 2.07^a	71.59 ± 4.21^b
	Week 4	11	398.18 ± 14.81^a	40.69 ± 4.21^b	31.75 ± 1.71^a	71.62 ± 2.57^b
	Week 6	11	429.22 ± 16.05^a	52.01 ± 3.58^b	28.91 ± 1.77^a	72.78 ± 2.78^b
	Week 8	11	458.16 ± 13.04^a^,^c	42.41 ± 4.28^b	29.02 ± 2.39^a	68.89 ± 5.62^b
High-dose YYHWM-H	Week 0	11	370.19 ± 15.67^a	62.63 ± 3.97^a	27.33 ± 2.57^a	67.20 ± 6.22^a
	Week 2	11	397.72 ± 16.15^a	48.80 ± 2.75^b	26.91 ± 3.06^a	71.78 ± 4.22^b
	Week 4	11	419.24 ± 16.24^a	49.32 ± 3.34^b	29.86 ± 1.75^a	69.73 ± 5.45^b
	Week 6	11	438.43 ± 22.51^a^,^b^,^c	47.09 ± 4.97^b	30.58 ± 3.15^a	70.45 ± 5.77^b
	Week 8	11	455.82 ± 21.74^a^,^b^,^c	48.29 ± 3.58^b	28.81 ± 2.24^a	68.68 ± 4.82^b
Vitacoenzyme	Week 0	11	365.41 ± 23.80^a	63.30 ± 2.95^a	26.05 ± 1.86^a	65.92 ± 5.92^a
	Week 2	11	379.43 ± 14.28^a	56.87 ± 3.64^b	28.04 ± 1.68^a	67.91 ± 4.44^b
	Week 4	11	395.63 ± 22.03^a	43.21 ± 2.97^b	25.67 ± 1.94^a	65.54 ± 3.40^b
	Week 6	11	422.27 ± 16.99^a	45.10 ± 4.62^b	29.15 ± 2.53^a	69.02 ± 5.31^b
	Week 8	11	444.35 ± 17.74^a^,^b	45.27 ± 3.32^b	30.24 ± 3.03^a	70.11 ± 4.27^b

^aP < 0.05 compared with blank control group.

^bP < 0.05 compared with model group.

^cP < 0.05 compared with model group.

YYHWM: Yangyin Huowei mixture.

Table 2 Effects of Yangyin Huowei mixture on serum PG and G-17 levels in rats (mean ± SD)

Group	n	PG-I (ng/mL)	PG-II (ng/mL)	PGR	G-17 (pg/mL)
Blank control	6	82.41 ± 3.53^d^,^e	23.06 ± 0.96^d^,^e	3.74 ± 0.17	493.09 ± 12.17^d^,^e
Model	6	38.52 ± 1.71^c^,^e	11.06 ± 0.70^c^,^e	3.72 ± 0.29	225.52 ± 17.44^c^,^e
Low-dose YYHWM	6	71.98 ± 4.26^c^,^d^,^e	18.44 ± 1.01^c^,^d^,^e	3.91 ± 0.28^b	433.82 ± 20.18^c^,^d^,^e
Medium-dose YYHWM	6	61.64 ± 3.18^c^,^d^,^e	16.94 ± 1.19^c^,^d^,^e	3.65 ± 0.30	375.25 ± 30.03^c^,^d^,^e
High-dose YYHWM	6	50.41 ± 3.53^b^,^c^,^d	15.33 ± 1.24^b^,^c^,^d	3.30 ± 0.29^a	329.22 ± 29.11^b^,^c^,^d
Vitacoenzyme	6	45.52 ± 5.71^c^,^d	13.06 ± 1.10^c^,^d	3.51 ± 0.57	283.53 ± 22.66^c^,^d
F value		115.63	99.35	2.525	111.46
P value		< 0.01	< 0.01	0.051	< 0.01

^aP < 0.05 compared with blank control group.

^bP < 0.05 compared with model group.

^cP < 0.01 compared with blank control group.

^dP < 0.01 compared with model group.

^eP < 0.01 compared with vitacoenzyme group.

YYHWM: Yangyin Huowei mixture.

Table 3 Effects of Yangyin Huowei mixture on serum levels of the inflammatory factors IL-1β, IL-6, and TNF-α in rats (mean ± SD, pg/mL)

Group	n	IL-1β	IL-6	TNF-α
Blank control	6	30.15 ± 3.07^e^,^f	69.05 ± 12.72^c^,^e	209.24 ± 11.62^c^,^e
Model	6	80.98 ± 4.47^d^,^f	110.85 ± 6.68^d^,^f	313.37 ± 36.77^d^,^f
Low-dose YYHWM	6	71.89 ± 3.03^d^,^e^,^f	100.70 ± 6.76^d^,^b^,^f	292.47 ± 12.89^d^,^f
Medium-dose YYHWM	6	46.08 ± 3.11^d^,^e^,^f	81.92 ± 6.14^a^,^e	245.79 ± 10.29^d^,^e
High-dose YYHWM	6	61.56 ± 4.02^d^,^e^,^f	89.20 ± 8.48^d^,^e	267.30 ± 9.31^c^,^d^,^e
Vitacoenzyme	6	52.17 ± 4.12^d^,^e	80.72 ± 6.04^a^,^e	239.54 ± 24.15^a^,^e
F value		148.76	20.44	21.17
P value		< 0.01	< 0.01	< 0.01

^aP < 0.05 compared with blank control group.

^bP < 0.05 compared with model group.

^cP < 0.05 compared with model group.

^dP < 0.01 compared with blank control group.

^eP < 0.01 compared with model group.

^fP < 0.01 compared with vitacoenzyme group.

YYHWM: Yangyin Huowei mixture.

Table 4 Effects of YYHWM on protein expression levels of IL-10, JAK1, and STAT3 in rat gastric tissues (mean ± SD)

Group	IL-10/GADPH	JAK1/GADPH	STAT3/GADPH
Blank control	0.47 ± 0.10^e	0.49 ± 0.05^e^,^f	0.24 ± 0.05^e^,^f
Model	1.11 ± 0.09^d^,^f	0.99 ± 0.07^d^,^f	1.04 ± 0.14^c^,^d
Low-dose YYHWM	0.76 ± 0.11^a^,^e	0.75 ± 0.07^d^,^e^,^f	1.07 ± 0.11^d^,^f
Medium-dose YYHWM	0.41 ± 0.12^c^,^e	0.69 ± 0.07^b^,^d^,^f	0.50 ± 0.13^e
High-dose YYHWM	0.19 ± 0.07^a^,^e^,^f	0.51 ± 0.05^d	0.55 ± 0.09^a^,^e
Vitacoenzyme	0.71 ± 0.08^e	0.38 ± 0.07^d	0.70 ± 0.04^b^,^d
F value	33.39	35.70	31.08
P value	< 0.01	< 0.01	< 0.01

^aP < 0.05 compared with blank control group.

^bP < 0.05 compared with model group.

^cP < 0.05 compared with model group.

^dP < 0.01 compared with blank control group.

^eP < 0.01 compared with model group.

^fP < 0.01 compared with vitacoenzyme group.

YYHWM: Yangyin Huowei mixture.

Citation: Xie SS, Zhi Y, Shao CM, Zeng BF. Yangyin Huowei mixture alleviates chronic atrophic gastritis by inhibiting the IL-10/JAK1/STAT3 pathway. World J Gastrointest Surg 2024; 16(7): 2296-2307
URL: https://www.wjgnet.com/1948-9366/full/v16/i7/2296.htm
DOI: https://dx.doi.org/10.4240/wjgs.v16.i7.2296